Tolerability and quality-of-life (QoL) results from the phase REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma

被引：0
|
作者：
Chau, I. [1 ]
Passalacqua, R. [2 ]
Zalcberg, J. R. [3 ,4 ]
Fuchs, C. S. [5 ,6 ]
Liepa, A. M. [7 ]
Hsu, Y. [8 ]
Schwartz, J. D. [9 ]
Koshiji, M. [10 ]
Tabernero, J. [11 ,12 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton, Surrey, England
[2] Ist Ospitalieri Cremona, Div Med Oncol, Cremona, Italy
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Univ Melbourne, Div Hematol & Med Oncol, Melbourne, Vic, Australia
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA
[7] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[8] ImClone Syst LLC, Global Stat Sci, Bridgewater, MA USA
[9] ImClone Syst LLC, Global Med Sci, Bridgewater, MA USA
[10] Eli Lilly & Co, Global Med Sci, Indianapolis, IN 46285 USA
[11] Vall dHebron Univ Hosp, Barcelona, Spain
[12] Univ Autonoma Barcelona, Dept Med Oncol, E-08193 Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2588
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [1] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results.
    Al-Batran, Salah-Eddin
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Muro, Kei
    Liepa, Astra M.
    Ballal, Shaila
    Emig, Michael
    Ohtsu, Atsushi
    Wilke, Hansjochen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
    Al-Batran, S. -E.
    Van Cutsem, E.
    Oh, S. C.
    Bodoky, G.
    Shimada, Y.
    Hironaka, S.
    Sugimoto, N.
    Lipatov, O. N.
    Kim, T. -Y.
    Cunningham, D.
    Rougier, P.
    Muro, K.
    Liepa, A. M.
    Chandrawansa, K.
    Emig, M.
    Ohtsu, A.
    Wilke, H.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 673 - 679
  • [3] QUALITY-OF-LIFE (QOL) RESULTS FROM THE PHASE 3 RAINBOW-ASIA STUDY OF RAMUCIRUMAB PLUS PACLITAXEL (RAM/PTX) VERSUS PLACEBO PLUS PACLITAXEL (PBO/PTX) IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (AGC)
    Xu, R.
    Shen, L.
    Qin, Y.
    Qin, S.
    Yin, X.
    Liu, B.
    Tanasanvimon, S.
    Zhou, C.
    Zhang, W.
    Zhou, L.
    [J]. VALUE IN HEALTH, 2021, 24 : S21 - S21
  • [4] Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD)
    Cascinu, S.
    Aprile, G.
    Pastorelli, D.
    Pinto, C.
    Bordonaro, R.
    Farina, G.
    Amoroso, D.
    Bilancia, D.
    Ciuffreda, L.
    Sartori, D.
    Falcone, A.
    Silvestris, N.
    Beretta, G. D.
    Buonadonna, A.
    Sobrero, A.
    Tamburini, E.
    Amoroso, V.
    Hsu, Y.
    Chandrawansa, K.
    Wilke, H.
    Fuchs, C.
    Passalacqua, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 90 - 90
  • [5] Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD and RAINBOW)
    Chau, I.
    Fuchs, C.
    Muro, K.
    Tomasek, J.
    Van Cutsem, E.
    Cho, J. Y.
    Oh, S. C.
    Safran, H.
    Bodoky, G.
    Shimada, Y.
    Dumitru, F.
    Passalacqua, R.
    Ohtsu, A.
    Hsu, Y.
    Liepa, A.
    Chandrawansa, K.
    Emig, M.
    Ferry, D.
    Wilke, H.
    Al-Batran, S. E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S448 - S449
  • [6] Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer
    Chau, I.
    Al-Batran, S-E.
    Barzi, A.
    Liepa, A. M.
    Cui, Z.
    Hsu, Y.
    Chin, S.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    -Davila, Rafael Santana
    Arkenau, Hendrik-Tobias
    Mi, Gu
    Jin, Jin
    Rege, Jessicca
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Cecchini, Michael
    Cleary, James M.
    Shyr, Yu
    Chao, Joseph
    Uboha, Nataliya
    Cho, May
    Shields, Anthony
    Pant, Shubham
    Goff, Laura
    Spencer, Kristen
    Kim, Edward
    Stein, Stacey
    Kortmansky, Jeremy S.
    Canosa, Sandra
    Sklar, Jeffrey
    Swisher, Elizabeth M.
    Radke, Marc
    Ivy, Percy
    Boerner, Scott
    Durecki, Diane E.
    Hsu, Chih-Yuan
    Lorusso, Patricia
    Lacy, Jill
    [J]. BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 476 - 482
  • [9] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Michael Cecchini
    James M. Cleary
    Yu Shyr
    Joseph Chao
    Nataliya Uboha
    May Cho
    Anthony Shields
    Shubham Pant
    Laura Goff
    Kristen Spencer
    Edward Kim
    Stacey Stein
    Jeremy S. Kortmansky
    Sandra Canosa
    Jeffrey Sklar
    Elizabeth M. Swisher
    Marc Radke
    Percy Ivy
    Scott Boerner
    Diane E. Durecki
    Chih-Yuan Hsu
    Patricia LoRusso
    Jill Lacy
    [J]. British Journal of Cancer, 2024, 130 : 476 - 482
  • [10] A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Mehta, Rutika
    Kim, Richard D.
    Shah, Neal
    Carballido, Estrella M.
    Kim, Youngchul
    Imanirad, Iman
    Kim, Dae Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345